Effect of Cognitive Behavioral Therapy on Clinical Disease Course in Adolescents and Young Adults With Inflammatory Bowel Disease and Subclinical Anxiety and/or Depression: Results of a Randomized Trial

This randomized trial studied the effect of cognitive behavioral therapy (CBT) for the treatment of subclinical anxiety and/or depression on disease course in young IBD patients. CBT did not influence time to relapse, clinical disease activity, C-reactive protein or calprotectin levels. Abstract Bac...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Inflammatory bowel diseases 2019-12, Vol.25 (12), p.1945-1956
Hauptverfasser: van den Brink, Gertrude, Stapersma, Luuk, Bom, Anna Sophia, Rizopolous, Dimitris, van der Woude, C Janneke, Stuyt, Rogier J L, Hendriks, Danielle M, van der Burg, Joyce A T, Beukers, Ruud, Korpershoek, Thea A, Theuns-Valks, Sabine D M, Utens, Elisabeth M W J, Escher, Johanna C
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This randomized trial studied the effect of cognitive behavioral therapy (CBT) for the treatment of subclinical anxiety and/or depression on disease course in young IBD patients. CBT did not influence time to relapse, clinical disease activity, C-reactive protein or calprotectin levels. Abstract Background Anxiety and depressive symptoms are prevalent in patients with inflammatory bowel disease (IBD) and may negatively influence disease course. Disease activity could be affected positively by treatment of psychological symptoms. We investigated the effect of cognitive behavioral therapy (CBT) on clinical disease course in 10–25-year-old IBD patients experiencing subclinical anxiety and/or depression. Methods In this multicenter parallel group randomized controlled trial, IBD patients were randomized to disease-specific CBT in addition to standard medical care (CBT + care us usual [CAU]) or CAU only. The primary outcome was time to first relapse in the first 12 months. Secondary outcomes were clinical disease activity, fecal calprotectin, and C-reactive protein (CRP). Survival analyses and linear mixed models were performed to compare groups. Results Seventy patients were randomized (CBT+CAU = 37, CAU = 33), with a mean age of 18.3 years (±50% < 18 y, 31.4% male, 51.4% Crohn’s disease, 93% in remission). Time to first relapse did not differ between patients in the CBT+CAU group vs the CAU group (n = 65, P = 0.915). Furthermore, clinical disease activity, fecal calprotectin, and CRP did not significantly change over time between/within both groups. Exploratory analyses in 10–18-year-old patients showed a 9% increase per month of fecal calprotectin and a 7% increase per month of serum CRP in the CAU group, which was not seen in the CAU+CBT group. Conclusions CBT did not influence time to relapse in young IBD patients with subclinical anxiety and/or depression. However, exploratory analyses may suggest a beneficial effect of CBT on inflammatory markers in children.
ISSN:1078-0998
1536-4844
1536-4844
DOI:10.1093/ibd/izz073